Top university research, cross-border data exchanges and access to mainland China’s large market have attracted Japanese firm Rohto Pharmaceutical to conduct clinical trials in Hong Kong, making it the first company from the country to partner with the city’s government under a flagship investment initiative. Rohto, known for its over-the-counter eye care and skincare products, is among the latest batch of 18 firms recruited by the Office for Attracting Strategic Enterprises (OASES), a...
Drug maker Rohto plans clinical trials in Hong Kong as OASES’ first Japan partner
SC
SCMP - China Feed 2By Elizabeth Cheung
EXECUTIVE SUMMARY
Top university research, cross-border data exchanges and access to mainland China’s large market have attracted Japanese firm Rohto Pharmaceutical to conduct clinical trials in Hong Kong, making it the first company from the country to partner with the city’s government under a flagship investment initiative. Rohto, known for its over-the-counter eye care and skincare products, is among the latest batch of 18 firms recruited by the Office for Attracting Strategic Enterprises (OASES), a...
Key Takeaways
- Drug maker Rohto plans clinical trials in Hong Kong as OASES’ first Japan partner.
- Rohto, known for its over-the-counter eye care and skincare products, is among the latest batch of 18 firms recruited by the Office for Attracting Strategic Enterprises (OASES), a...
- Rohto, known for its over-the-counter eye care and skincare products, is among the latest batch of 18 firms recruited by the Office for Attracting Strategic Enterprises (OASES), a...
Read Complete Original Article
Published originally on SCMP - China Feed 2
